Flu prevention setback for Inavir: Biota blames high Japanese hygiene standards
This article was originally published in Scrip
Executive Summary
Biota has reported disappointing results in a Phase III trial designed to study the prophylactic potential of the second-generation flu product CS-8958 (laninamivir), which is already marketed as a treatment in Japan by Daiichi Sankyo, the drug's originator, as Inavir. The Australian company's share price fell by almost 10% to 92 Australian cents on the news.